RxDoctor Payments Data

Melanie Yawn, NP

Family · Albany, GANPI 1295149029

Payments from drug & device makers

$1,324in general payments, 2019–2025

Across 80 payments — averaging $16.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$437
  • Novo Nordisk$273
  • Amgen$169
  • AstraZeneca$116
  • Lilly USA, LLC$101
  • Merck$49
  • plus $178 from 7 others

What the payments were for

  • Food & beverage$1,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,324 in reported general payments places this provider in the 70th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$21,182
Medicare patients
71
Services billed
310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$51,186
OzempicSemaglutide42$50,413
JardianceEmpagliflozin43$46,171
Liothyronine Sodium429$28,608
VraylarCariprazine Hcl14$19,950
TrulicityDulaglutide12$13,461
LinzessLinaclotide11$10,779
GlyxambiEmpagliflozin/Linagliptin13$4,793
Levothyroxine Sodium161$1,652
ProgesteroneProgesterone, Micronized34$1,546
SynthroidLevothyroxine Sodium14$1,001
Losartan Potassium53$484
Pantoprazole Sodium56$405
Atorvastatin Calcium48$399
Tamsulosin Hcl30$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$101$64,64861 claims
Boehringer IngelheimJardiance, Glyxambi$39$50,96456 claims
Novo NordiskOzempic$273$50,41342 claims
AbbVieVraylar, Linzess, Synthroid$437$31,73039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,258 family providers in Georgia.

Other family in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →